RxDoctor Payments Data

Steven Song, MD

Family Medicine · Chicago, ILNPI 1538540984

Payments from drug & device makers

$241in general payments, 2019–2025

Across 12 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$63
  • Johnson & Johnson$51
  • Sanofi-aventis U.S. LLC$45
  • Edwards Lifesciences$20
  • AstraZeneca$16
  • Exact Sciences$16
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$241 in reported general payments places this provider in the 50th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$17,458
Medicare patients
54
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$141,952
JardianceEmpagliflozin87$127,653
RybelsusSemaglutide66$114,222
EliquisApixaban47$61,644
JanuviaSitagliptin Phosphate40$53,734
VemlidyTenofovir Alafenamide20$28,617
XareltoRivaroxaban24$26,343
Breo ElliptaFluticasone/Vilanterol51$24,117
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$18,830
Incruse ElliptaUmeclidinium Bromide32$12,546
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$8,579
Novolog FlexpenInsulin Aspart30$5,917
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,882
Atorvastatin Calcium846$3,203
Amlodipine Besylate537$2,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$63$256,174158 claims
Johnson & JohnsonXarelto$51$26,34324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →